Noble Financial Reaffirms Buy Rating for Anavex Life Sciences (AVXL)
Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating reiterated by Noble Financial in a note issued to investors on Tuesday.
AVXL has been the subject of several other research reports. Zacks Investment Research raised shares of Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research note on Monday, August 28th. Maxim Group set a $15.00 price target on shares of Anavex Life Sciences and gave the company a “buy” rating in a research note on Thursday, October 12th. Finally, ValuEngine downgraded shares of Anavex Life Sciences from a “hold” rating to a “sell” rating in a research note on Tuesday, November 21st.
Anavex Life Sciences (AVXL) traded down $0.10 during trading on Tuesday, hitting $3.20. 431,900 shares of the stock traded hands, compared to its average volume of 404,652. Anavex Life Sciences has a 1 year low of $3.01 and a 1 year high of $6.64.
Several institutional investors have recently bought and sold shares of the company. SNS Financial Group LLC bought a new position in Anavex Life Sciences in the third quarter worth approximately $290,000. Northern Trust Corp raised its stake in Anavex Life Sciences by 16.0% in the second quarter. Northern Trust Corp now owns 429,073 shares of the biotechnology company’s stock worth $2,282,000 after buying an additional 59,069 shares in the last quarter. Vanguard Group Inc. raised its stake in Anavex Life Sciences by 13.1% in the first quarter. Vanguard Group Inc. now owns 1,485,681 shares of the biotechnology company’s stock worth $8,528,000 after buying an additional 171,577 shares in the last quarter. Virtu KCG Holdings LLC bought a new position in Anavex Life Sciences in the second quarter worth approximately $186,000. Finally, Geode Capital Management LLC raised its stake in Anavex Life Sciences by 16.8% in the first quarter. Geode Capital Management LLC now owns 276,974 shares of the biotechnology company’s stock worth $1,589,000 after buying an additional 39,934 shares in the last quarter. 23.88% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/13/noble-financial-reaffirms-buy-rating-for-anavex-life-sciences-avxl.html.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.